I Application of the prediction tool

The relevant treatment information table is provided for input values. The predicted risks of POI from age 21 to 39 are plotted based on the information in the table. Two examples are presented below.

Example 1 (Table B1 and Figure I.1): Suppose one girl (race: white) was diagnosed with Leukemia at age 2. During the cancer treatment, she received radiotherapy including the irradiation to two ovaries and pituitary. The lower cumulative doses received between both side ovaries was 8.1 cGy and the pituitary received 1800 cGy radiation doses. Her chemotherapy included a total cumulative cyclophosphamide dose 13007 mg/m2, daunorubicin dose 520 mg/m2, doxorubicin dose 90 mg/m2, methotrexate dose 460 mg/m2, and VM 26 dose 6338 mg/m2.

Predicted risks of POI from age 21 to 39 for Example 1

Figure I.1: Predicted risks of POI from age 21 to 39 for Example 1

Example 2 (Table B2 and Figure I.2): Suppose one girl (race: Asian or Pacific Islander) was diagnosed with Non-Hodgkin lymphoma at age 14. During the cancer treatment, she received radiotherapy including the irradiation to two ovaries and pituitary. The lower cumulative doses received between both side ovaries was 2.3 cGy and the pituitary received 47 cGy radiation doses. Her chemotherapy included a total cumulative BCNU 300 mg/m2, cyclophosphamide dose 15576 mg/m2, daunorubicin dose 118 mg/m2, doxorubicin dose 181 mg/m2, methotrexate dose 7934 mg/m2, and VP 16 dose 6184 mg/m2.

Predicted risks of POI from age 21 to 39 for Example 2

Figure I.2: Predicted risks of POI from age 21 to 39 for Example 2